Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mika Sunakawa-Kii"'
Autor:
Hideto Tamura, Rimpei Morita, Koiti Inokuchi, Mika Sunakawa-Kii, Hiroshi Handa, Takumi Ito, Junichi Yamamoto, Mariko Ishibashi
We previously showed that the interaction of programmed death-ligand 1 (PD-L1) on multiple myeloma (MM) cells with PD-1 not only inhibits tumor-specific cytotoxic T-lymphocyte activity via the PD-1 signaling pathway but also induces drug resistance v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c24f7df0cc6a46b3d564efeb21b942b
https://doi.org/10.1158/1535-7163.c.6543444.v1
https://doi.org/10.1158/1535-7163.c.6543444.v1
Autor:
Hideto Tamura, Rimpei Morita, Koiti Inokuchi, Mika Sunakawa-Kii, Hiroshi Handa, Takumi Ito, Junichi Yamamoto, Mariko Ishibashi
Supplementary Materials and methods; Supplementary Table S1: Cell characteristics and phenotypes of MM cell lines; Supplementary Table S2: Characteristics of patients with newly diagnosed MM in Figure 1H; Supplementary Table S3: Primer and shRNA sequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3bf352fe8190d2ff114f9b41538dad
https://doi.org/10.1158/1535-7163.22522599.v1
https://doi.org/10.1158/1535-7163.22522599.v1
Autor:
Ryosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, Makoto Sasaki, Yoichi Imai, Norina Tanaka, Shigeki Ito, Mika Sunakawa-Kii, Yuta Kaito, Toshio Asayama, Norio Komatsu, Junji Tanaka, Takeshi Odajima, Hiroki Sugimori, Hiroki Yamaguchi, Koiti Inokuchi, Hideto Tamura
Publikováno v:
Experimental Hematology. 121:38-47.e2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64446e37d71657cddd4c597894a3d0ff
https://doi.org/10.1016/j.exphem.2023.01.006
https://doi.org/10.1016/j.exphem.2023.01.006
Autor:
Mariko Ishibashi, Toshio Asayama, Yuta Kaito, Ryosuke Kinoshita, Yasuko Kuribayashi, Koiti Inokuchi, Mika Sunakawa-Kii, Rimpei Morita, Hideto Tamura
Publikováno v:
Experimental hematology. 90
The signaling lymphocytic activation molecule family 3 (SLAMF3) is highly expressed on plasma cells from patients with multiple myeloma (MM) and induces high malignant potential by ERK signaling mediated via the interaction with adaptor proteins SHP2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff8171e81ad583def29c13c23e24d26
https://pubmed.ncbi.nlm.nih.gov/32818503
https://pubmed.ncbi.nlm.nih.gov/32818503
Publikováno v:
Cancers
Cancers, Vol 12, Iss 924, p 924 (2020)
Cancers, Vol 12, Iss 924, p 924 (2020)
PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b829c8b3fe54b6de6282ce4e257e2b
http://europepmc.org/articles/PMC7226506
http://europepmc.org/articles/PMC7226506
Autor:
Rimpei Morita, Hiroshi Handa, Takumi Ito, Koiti Inokuchi, Mika Sunakawa-Kii, Mariko Ishibashi, Hideto Tamura, Junichi Yamamoto
Publikováno v:
Molecular cancer therapeutics. 20(7)
We previously showed that the interaction of programmed death-ligand 1 (PD-L1) on multiple myeloma (MM) cells with PD-1 not only inhibits tumor-specific cytotoxic T-lymphocyte activity via the PD-1 signaling pathway but also induces drug resistance v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::499707ddf6c7ee87fc6a61d5c54bdeef
https://pubmed.ncbi.nlm.nih.gov/33879556
https://pubmed.ncbi.nlm.nih.gov/33879556